Immediate Impact
46 standout
Citing Papers
AXL signaling in cancer: from molecular insights to targeted therapies
2025 Standout
The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
Works of Daniele Rizzi being referenced
AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)
2018
Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial
2014
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Daniele Rizzi | 133 | 94 | 58 | 89 | 15 | 181 | |
| Francesca Daniel | 121 | 54 | 58 | 68 | 21 | 174 | |
| Jane Banerji | 130 | 62 | 41 | 149 | 10 | 195 | |
| Carole A. Harris | 130 | 68 | 28 | 48 | 21 | 175 | |
| Federica Villa | 184 | 74 | 26 | 76 | 15 | 212 | |
| Stéphane Jacquot | 108 | 33 | 85 | 101 | 13 | 178 | |
| Dany Gholam | 117 | 33 | 120 | 73 | 16 | 282 | |
| James Orsini | 152 | 146 | 22 | 33 | 15 | 218 | |
| Emerik Österlund | 89 | 29 | 41 | 58 | 14 | 127 | |
| Catherine Leger | 196 | 88 | 70 | 30 | 10 | 232 | |
| K. Lorizzo | 155 | 85 | 27 | 35 | 20 | 225 |
All Works
Loading papers...